{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:06:34Z","timestamp":1788552394917,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"DOI":"10.7759\/cureus.106751","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:40:42Z","timestamp":1775796042000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.7759","author":[{"given":"Sukainnya","family":"Buragohain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrani","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyajyoti","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himangshu","family":"Malakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipul Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murchana","family":"Khound","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonmoni","family":"Lahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00124","article-title":"Poly cystic ovarian syndrome: an updated overview","volume":"7","author":"El Hayek S","year":"2016","unstructured":"El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016, 7:124. 10.3389\/fphys.2016.00124","journal-title":"Front Physiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00078","article-title":"Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls","volume":"3","author":"Witchel SF","year":"2019","unstructured":"Witchel SF, Oberfield SE, Pe\u00f1a AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019, 3:1545-73. 10.1210\/js.2019-00078","journal-title":"J Endocr Soc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-01091-0","article-title":"Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment","volume":"16","author":"Zhao H","year":"2023","unstructured":"Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023, 16:9. 10.1186\/s13048-022-01091-0","journal-title":"J Ovarian Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44493","article-title":"Role of metformin in polycystic ovary syndrome (PCOS)-related infertility","volume":"15","author":"Attia GM","year":"2023","unstructured":"Attia GM, Almouteri MM, Alnakhli FT. Role of metformin in polycystic ovary syndrome (PCOS)-related infertility. Cureus. 2023, 15:e44493. 10.7759\/cureus.44493","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68390","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review","volume":"16","author":"Hamed K","year":"2024","unstructured":"Hamed K, Alosaimi MN, Ali BA, et al.. Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus. 2024, 16:e68390. 10.7759\/cureus.68390","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2019.04.017","article-title":"GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis","volume":"39","author":"Han Y","year":"2019","unstructured":"Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019, 39:332-42. 10.1016\/j.rbmo.2019.04.017","journal-title":"Reprod Biomed Online"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13061113","article-title":"Current guidelines for diagnosing PCOS","volume":"13","author":"Christ JP","year":"2023","unstructured":"Christ JP, Cedars MI. Current guidelines for diagnosing PCOS. Diagnostics (Basel). 2023, 13:10.3390\/diagnostics13061113","journal-title":"Diagnostics (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref10","unstructured":"Review Manager (RevMan) [computer program]. Version 5.4. (2020). http.\/\/revman.cochrane.org."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch KE","year":"2022","unstructured":"Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022, 118:371-81. 10.1016\/j.fertnstert.2022.04.027","journal-title":"Fertil Steril"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin","volume":"170","author":"Jensterle Sever M","year":"2014","unstructured":"Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014, 170:451-9. 10.1530\/EJE-13-0797","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study","volume":"8","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Salamun V, Kocjan T, Vrtacnik Bokal E, Janez A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J Ovarian Res. 2015, 8:32. 10.1186\/s13048-015-0161-3","journal-title":"J Ovarian Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/BF03401383","article-title":"A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome","volume":"14","author":"Jensterle M","year":"2015","unstructured":"Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens). 2015, 14:81-90. 10.1007\/BF03401383","journal-title":"Hormones (Athens)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-017-0155-9","article-title":"Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial","volume":"17","author":"Jensterle M","year":"2017","unstructured":"Jensterle M, Kravos NA, Gori\u010dar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017, 17:5. 10.1186\/s12902-017-0155-9","journal-title":"BMC Endocr Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001712","article-title":"Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome","volume":"134","author":"Ma RL","year":"2021","unstructured":"Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight\/obese women with polycystic ovary syndrome. Chin Med J (Engl). 2021, 134:2882-9. 10.1097\/CM9.0000000000001712","journal-title":"Chin Med J (Engl)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2017.06.003","article-title":"Short-term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight\/obese PCOS women","volume":"5","author":"Zheng SY","year":"2017","unstructured":"Zheng SY, Li CW, Fang P, et al.. Short-term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight\/obese PCOS women. Obes Med. 2017, 5:1-5. 10.1016\/j.obmed.2017.06.003","journal-title":"Obes Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome","volume":"87","author":"Liu X","year":"2017","unstructured":"Liu X, Zhang Y, Zheng SY, et al.. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017, 87:767-74. 10.1111\/cen.13454","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/nu15030556","article-title":"Effects of a dulaglutide plus calorie-restricted diet versus a calorie-restricted diet on visceral fat and metabolic profiles in women with polycystic ovary syndrome: a randomized controlled trial","volume":"15","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Qu Z, Lu T, et al.. Effects of a dulaglutide plus calorie-restricted diet versus a calorie-restricted diet on visceral fat and metabolic profiles in women with polycystic ovary syndrome: a randomized controlled trial. Nutrients. 2023, 15:10.3390\/nu15030556","journal-title":"Nutrients"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14944","article-title":"Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity","volume":"25","author":"Jensterle M","year":"2023","unstructured":"Jensterle M, Ferjan S, Le\u017eai\u010d L, et al.. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023, 25:975-84. 10.1111\/dom.14944","journal-title":"Diabetes Obes Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108935","article-title":"Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study","volume":"178","author":"Jensterle M","year":"2021","unstructured":"Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Jane\u017e A. Semaglutide reduces fat accumulation in the tongue: a randomized single-blind, pilot study. Diabetes Res Clin Pract. 2021, 178:108935. 10.1016\/j.diabres.2021.108935","journal-title":"Diabetes Res Clin Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa692","article-title":"Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study","volume":"106","author":"Tao T","year":"2021","unstructured":"Tao T, Zhang Y, Zhu YC, et al.. Exenatide, metformin, or both for prediabetes in PCOS: a randomized, open-label, parallel-group controlled study. J Clin Endocrinol Metab. 2021, 106:e1420-32. 10.1210\/clinem\/dgaa692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/4288004","article-title":"Action mechanisms of metformin combined with exenatide and metformin only in the treatment of PCOS in obese patients","volume":"2023","author":"Gan J","year":"2023","unstructured":"Gan J, Chen J, Ma RL, et al.. Action mechanisms of metformin combined with exenatide and metformin only in the treatment of PCOS in obese patients. Int J Endocrinol. 2023, 2023:4288004. 10.1155\/2023\/4288004","journal-title":"Int J Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.945609","article-title":"Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome","volume":"13","author":"Xing C","year":"2022","unstructured":"Xing C, Zhao H, Zhang J, He B. Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2022, 13:945609. 10.3389\/fendo.2022.945609","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03487-4","article-title":"Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial","volume":"83","author":"Liao M","year":"2024","unstructured":"Liao M, Li X, Zhang H, et al.. Effects and plasma proteomic analysis of GLP-1RA versus CPA\/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial. Endocrine. 2024, 83:227-41. 10.1007\/s12020-023-03487-4","journal-title":"Endocrine"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial","volume":"35","author":"Nylander M","year":"2017","unstructured":"Nylander M, Fr\u00f8ssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017, 35:121-7. 10.1016\/j.rbmo.2017.03.023","journal-title":"Reprod Biomed Online"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch K","year":"2008","unstructured":"Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008, 93:2670-8. 10.1210\/jc.2008-0115","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun V","year":"2018","unstructured":"Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018, 179:1-11. 10.1530\/EJE-18-0175","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478404-effectiveness-of-glp-1-receptor-agonists-in-patients-with-polycystic-ovary-syndrome-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:40:56Z","timestamp":1775796056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478404-effectiveness-of-glp-1-receptor-agonists-in-patients-with-polycystic-ovary-syndrome-a-systematic-review-and-meta-analysis-of-randomised-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.106751","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}